Topotecan in previously treated advanced urothelial carcinoma: An ECOG phase II trial

Robert S. Witte, Judith Manola, Patrick A. Burch, Timothy Kuzel, Eric L. Weinshel, Patrick J. Loehrer

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Chemotherapeutic agents are playing an increasing role in the management of urothelial carcinoma. Despite recent advances in the treatment of this disease there continues to be a need to identify new active agents and their toxicity spectra. Topotecan is an agent as yet unstudied in bladder cancer. Methods: Ambulatory patients with progressive advanced urothelial carcinoma following prior systemic chemotherapy were treated with topotecan 1.5 mg/m2 intravenously (IV) daily for 5 days every three weeks for 6 cycles. Doses were modified for leukopenic fever, thrombocytopenic bleeding, and any grade 3 or 4 (NCI common toxicity criteria) toxicity. Results: Forty-four eligible patients entered the trial. There were 4 partial responses for an overall response rate of 9.1% (exact 95%; two-stage binomial CI, 2.9% to 25.5%). Major identified toxicities were gastrointestinal and myelosuppression. There were no treatment-related deaths. Conclusions: Topotecan at this dose and schedule has minimal activity in previously treated patients with advanced urothelial carcinoma. Toxicities can be severe but are manageable.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalInvestigational New Drugs
Volume16
Issue number2
DOIs
StatePublished - Nov 11 1998

Fingerprint

Topotecan
Carcinoma
Urinary Bladder Neoplasms
Appointments and Schedules
Fever
Hemorrhage
Drug Therapy
Therapeutics

Keywords

  • Bladder cancer
  • Topotecan
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Topotecan in previously treated advanced urothelial carcinoma : An ECOG phase II trial. / Witte, Robert S.; Manola, Judith; Burch, Patrick A.; Kuzel, Timothy; Weinshel, Eric L.; Loehrer, Patrick J.

In: Investigational New Drugs, Vol. 16, No. 2, 11.11.1998, p. 191-195.

Research output: Contribution to journalArticle

Witte, Robert S. ; Manola, Judith ; Burch, Patrick A. ; Kuzel, Timothy ; Weinshel, Eric L. ; Loehrer, Patrick J. / Topotecan in previously treated advanced urothelial carcinoma : An ECOG phase II trial. In: Investigational New Drugs. 1998 ; Vol. 16, No. 2. pp. 191-195.
@article{b6887a20c2624f8097bc67a66d4ae18c,
title = "Topotecan in previously treated advanced urothelial carcinoma: An ECOG phase II trial",
abstract = "Background: Chemotherapeutic agents are playing an increasing role in the management of urothelial carcinoma. Despite recent advances in the treatment of this disease there continues to be a need to identify new active agents and their toxicity spectra. Topotecan is an agent as yet unstudied in bladder cancer. Methods: Ambulatory patients with progressive advanced urothelial carcinoma following prior systemic chemotherapy were treated with topotecan 1.5 mg/m2 intravenously (IV) daily for 5 days every three weeks for 6 cycles. Doses were modified for leukopenic fever, thrombocytopenic bleeding, and any grade 3 or 4 (NCI common toxicity criteria) toxicity. Results: Forty-four eligible patients entered the trial. There were 4 partial responses for an overall response rate of 9.1{\%} (exact 95{\%}; two-stage binomial CI, 2.9{\%} to 25.5{\%}). Major identified toxicities were gastrointestinal and myelosuppression. There were no treatment-related deaths. Conclusions: Topotecan at this dose and schedule has minimal activity in previously treated patients with advanced urothelial carcinoma. Toxicities can be severe but are manageable.",
keywords = "Bladder cancer, Topotecan, Urothelial carcinoma",
author = "Witte, {Robert S.} and Judith Manola and Burch, {Patrick A.} and Timothy Kuzel and Weinshel, {Eric L.} and Loehrer, {Patrick J.}",
year = "1998",
month = "11",
day = "11",
doi = "10.1023/A:1006159525793",
language = "English (US)",
volume = "16",
pages = "191--195",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Topotecan in previously treated advanced urothelial carcinoma

T2 - An ECOG phase II trial

AU - Witte, Robert S.

AU - Manola, Judith

AU - Burch, Patrick A.

AU - Kuzel, Timothy

AU - Weinshel, Eric L.

AU - Loehrer, Patrick J.

PY - 1998/11/11

Y1 - 1998/11/11

N2 - Background: Chemotherapeutic agents are playing an increasing role in the management of urothelial carcinoma. Despite recent advances in the treatment of this disease there continues to be a need to identify new active agents and their toxicity spectra. Topotecan is an agent as yet unstudied in bladder cancer. Methods: Ambulatory patients with progressive advanced urothelial carcinoma following prior systemic chemotherapy were treated with topotecan 1.5 mg/m2 intravenously (IV) daily for 5 days every three weeks for 6 cycles. Doses were modified for leukopenic fever, thrombocytopenic bleeding, and any grade 3 or 4 (NCI common toxicity criteria) toxicity. Results: Forty-four eligible patients entered the trial. There were 4 partial responses for an overall response rate of 9.1% (exact 95%; two-stage binomial CI, 2.9% to 25.5%). Major identified toxicities were gastrointestinal and myelosuppression. There were no treatment-related deaths. Conclusions: Topotecan at this dose and schedule has minimal activity in previously treated patients with advanced urothelial carcinoma. Toxicities can be severe but are manageable.

AB - Background: Chemotherapeutic agents are playing an increasing role in the management of urothelial carcinoma. Despite recent advances in the treatment of this disease there continues to be a need to identify new active agents and their toxicity spectra. Topotecan is an agent as yet unstudied in bladder cancer. Methods: Ambulatory patients with progressive advanced urothelial carcinoma following prior systemic chemotherapy were treated with topotecan 1.5 mg/m2 intravenously (IV) daily for 5 days every three weeks for 6 cycles. Doses were modified for leukopenic fever, thrombocytopenic bleeding, and any grade 3 or 4 (NCI common toxicity criteria) toxicity. Results: Forty-four eligible patients entered the trial. There were 4 partial responses for an overall response rate of 9.1% (exact 95%; two-stage binomial CI, 2.9% to 25.5%). Major identified toxicities were gastrointestinal and myelosuppression. There were no treatment-related deaths. Conclusions: Topotecan at this dose and schedule has minimal activity in previously treated patients with advanced urothelial carcinoma. Toxicities can be severe but are manageable.

KW - Bladder cancer

KW - Topotecan

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0031731552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031731552&partnerID=8YFLogxK

U2 - 10.1023/A:1006159525793

DO - 10.1023/A:1006159525793

M3 - Article

C2 - 9848585

AN - SCOPUS:0031731552

VL - 16

SP - 191

EP - 195

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -